Medical News Today -
7 Jan 2014 10:00
A protein that has been at the centre of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA).The most advanced version of αvβ3-integrin antagonists failed clinical trials to treat aggressive forms of brain cancer.But research published in the American Heart Association's journal Circulation Research shows that targeting the protein in question could still be vital in stopping the growth of tumours.
Share this Article